Compare · FOXW vs NVO
FOXW vs NVO
Side-by-side comparison of FoxWayne Enterprises Acquisition Corp. (FOXW) and Novo Nordisk A/S (NVO): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both FOXW and NVO operate in Biotechnology: Pharmaceutical Preparations (Health Care), so they compete in similar markets.
- NVO is the larger of the two at $183.15B, about 2543.3x FOXW ($72.0M).
- NVO has hit the wire 8 times in the past 4 weeks while FOXW has been quiet.
- NVO has more recent analyst coverage (25 ratings vs 0 for FOXW).
- Company
- FoxWayne Enterprises Acquisition Corp.
- Novo Nordisk A/S
- Price
- $10.14+0.10%
- $41.01-4.51%
- Market cap
- $72.0M
- $183.15B
- 1M return
- -
- -10.44%
- 1Y return
- -
- -45.66%
- Industry
- Biotechnology: Pharmaceutical Preparations
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NASDAQ
- NYSE
- IPO
- 2021
- News (4w)
- 0
- 8
- Recent ratings
- 0
- 25
FoxWayne Enterprises Acquisition Corp.
Foxwayne Enterprises Acquisition Corp. does not have significant business. It focuses on effecting a merger, capital stock exchange, asset acquisition, stock purchase, reorganization, or similar business combination with one or more businesses. Foxwayne Enterprises Acquisition Corp. was incorporated in 2020 and is based in New York, New York.
Novo Nordisk A/S
Novo Nordisk A/S, a healthcare company, engages in the research, development, manufacture, and marketing of pharmaceutical products worldwide. It operates in two segments, Diabetes and Obesity care, and Biopharm. The Diabetes and Obesity care segment provides products in the areas of insulins, GLP-1 and related delivery systems, oral antidiabetic products, obesity, and other chronic diseases. The Biopharmaceuticals segment offers products in the areas of haemophilia, growth disorders, and hormone replacement therapy. The company collaboration agreements with Lund University to develop treatment for Parkinson's diseases; and bluebird bio, Inc. to develop genome editing treatments for children and adult patients. Novo Nordisk A/S also has a research collaboration with Lumen Bioscience, Inc. to explore strategies for delivering oral biologics for cardiometabolic disease. The company was founded in 1923 and is headquartered in Bagsvaerd, Denmark.
Latest FOXW
- SEC Form SC 13G/A filed by FoxWayne Enterprises Acquisition Corp. (Amendment)
- SEC Form SC 13G/A filed by FoxWayne Enterprises Acquisition Corp. (Amendment)
- SEC Form SC 13G/A filed by FoxWayne Enterprises Acquisition Corp. (Amendment)
- SEC Form SC 13G filed by FoxWayne Enterprises Acquisition Corp.
- SEC Form SC 13G/A filed by FoxWayne Enterprises Acquisition Corp. (Amendment)
- SEC Form SC 13G filed by FoxWayne Enterprises Acquisition Corp.
- SEC Form SC 13G filed by FoxWayne Enterprises Acquisition Corp.
- SEC Form SC 13G/A filed by FoxWayne Enterprises Acquisition Corp. (Amendment)
- SEC Form SC 13G/A filed by FoxWayne Enterprises Acquisition Corp. (Amendment)
- SEC Form SC 13G/A filed by FoxWayne Enterprises Acquisition Corp. (Amendment)
Latest NVO
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form SD filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- Peptide-Based Health Industry Positioned for Explosive Long-Term Growth Across Global Wellness Markets
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- The $59B Quiet Shift Reshaping How Patients Access Care